A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the treatment of CD30-expressing malignancies. AFM13 recruits natural killer (NK) cells via binding to CD16A as immune effector cells. In this phase 1 dose-escalation study, 28 patients with heavily pretreated relap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Rothe, Achim, Sasse, Stephanie, Topp, Max S., Eichenauer, Dennis A., Hummel, Horst, Reiners, Katrin S., Dietlein, Markus, Kuhnert, Georg, Kessler, Joerg, Buerkle, Carolin, Ravic, Miroslav, Knackmuss, Stefan, Marschner, Jens-Peter, Pogge von Strandmann, Elke, Borchmann, Peter, Engert, Andreas
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4528081/
https://ncbi.nlm.nih.gov/pubmed/25887777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-12-614636
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados